Form 4: Intellia Therapeutics Director Georgia Keresty Granted Significant Equity Awards

Intellia Therapeutics, Inc. Director Georgia Keresty was granted 8,000 restricted stock units and options to purchase 11,450 shares of common stock, effective June 11, 2025.

Summary

• Intellia Therapeutics, Inc. (NTLA) Director Georgia Keresty was granted equity awards on June 11, 2025.
• The awards include 8,000 restricted stock units (RSUs) for common stock, granted at a price of $0.00 per unit.
• Following this grant, Ms. Keresty will beneficially own 31,883 shares of common stock directly.
• Additionally, Ms. Keresty was granted stock options to purchase 11,450 shares of common stock at an exercise price of $8.37 per share, also granted at a price of $0.00.
• These options will vest in full on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders following the grant date.
• The stock options have an expiration date of June 10, 2035.
• The filing also includes a Limited Power of Attorney, dated October 31, 2024, authorizing James Basta and Edward Dulac to execute SEC filings on behalf of Ms. Keresty.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is generally a positive sign of continued alignment between management and shareholder interests. It does not contain any negative financial or operational news.

Positives

• The grant of 8,000 restricted stock units and 11,450 stock options to Director Georgia Keresty indicates continued alignment of management's interests with shareholder value.
• The $0.00 grant price for both RSUs and options suggests these are incentive-based awards, common for director compensation, reinforcing commitment.

Future Outlook

The document indicates future vesting events for the granted stock options, which will occur on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders following the grant date.

Industry Context

This Form 4 filing reflects standard compensation practices for directors in the biotechnology industry, where equity grants are a common method to align director incentives with long-term company performance and shareholder interests. Intellia Therapeutics, a leader in CRISPR-based gene editing, uses such grants to retain and motivate key personnel.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a standard practice in the biotechnology and pharmaceutical sectors for executive and board compensation, aiming to align their interests with long-term shareholder value.
• The $0.00 grant price for RSUs and options is typical for incentive-based equity awards, reflecting compensation rather than a purchase.
• The vesting schedule (one year or next annual meeting) is a common short-to-medium term incentive structure seen across comparable biotech firms like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) for similar director grants, ensuring continued engagement.

Corporate Governance

Related Party Transactions

• The grant of 8,000 restricted stock units and 11,450 stock options to Georgia Keresty, a director of Intellia Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's long-term performance, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on employees is indicated, but such grants are part of a broader compensation philosophy that may influence overall company culture and talent retention strategies.
• Management: The grants serve as an incentive for the director to contribute to the company's success and maintain their commitment.

Next Steps

• The 11,450 stock options are scheduled to vest in full on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders following the grant date.

Key Dates

Recommendation

Keywords

Intellia Therapeutics, NTLA, SEC Form 4, Insider Trading, Stock Grant, Restricted Stock Units, Stock Options, Director Compensation, Equity Awards, Biotechnology, CRISPR